Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cholestin

This article was originally published in The Tan Sheet

Executive Summary

Cholestin: FDA agrees to accept additional data from Pharmanex following the Jan. 30 close of the public comment period on the regulatory status of Cholestin, which is marketed by the company as a dietary supplement for healthy cholesterol. At a Jan. 20 meeting with the agency, Pharmanex requested more time to reply to any "significant submissions" made at the end of the comment period. Merck filed substantial comments Jan. 30 arguing that Cholestin should be considered an unapproved new drug ("The Tan Sheet" Feb. 9, pp. 17-18). The product contains HMG-CoA reductase inhibitors including lovastatin, the active ingredient in Merck's prescription cholesterol-reducing drug, Mevacor...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel